Goldman Sachs Group Inc. lowered its stake in shares of Entellus Medical, Inc. (NASDAQ:ENTL) by 4.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 29,355 shares of the medical technology company’s stock after selling 1,325 shares during the quarter. Goldman Sachs Group Inc. owned 0.12% of Entellus Medical worth $486,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ENTL. Frontier Capital Management Co. LLC increased its position in shares of Entellus Medical by 85.0% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock valued at $14,347,000 after purchasing an additional 397,953 shares during the last quarter. Tekla Capital Management LLC purchased a new position in Entellus Medical during the 2nd quarter valued at $5,655,000. Nicholas Company Inc. boosted its holdings in Entellus Medical by 1,052.3% during the 2nd quarter. Nicholas Company Inc. now owns 247,685 shares of the medical technology company’s stock valued at $4,101,000 after acquiring an additional 226,190 shares during the period. Vanguard Group Inc. boosted its holdings in Entellus Medical by 77.8% during the 1st quarter. Vanguard Group Inc. now owns 424,823 shares of the medical technology company’s stock valued at $5,862,000 after acquiring an additional 185,833 shares during the period. Finally, First Manhattan Co. purchased a new position in Entellus Medical during the 2nd quarter valued at $2,876,000. 70.12% of the stock is currently owned by hedge funds and other institutional investors.

ENTL has been the subject of a number of recent analyst reports. BidaskClub cut Entellus Medical from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Piper Jaffray Companies restated a “buy” rating and set a $21.00 price objective on shares of Entellus Medical in a report on Tuesday, August 22nd. Finally, Canaccord Genuity restated a “hold” rating and set a $17.00 price objective on shares of Entellus Medical in a report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $21.17.

WARNING: “Goldman Sachs Group Inc. Has $486,000 Stake in Entellus Medical, Inc. (ENTL)” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/11/14/goldman-sachs-group-inc-has-486000-stake-in-entellus-medical-inc-entl.html.

Shares of Entellus Medical, Inc. (ENTL) opened at $15.98 on Tuesday. Entellus Medical, Inc. has a 1-year low of $11.47 and a 1-year high of $20.34. The company has a current ratio of 1.92, a quick ratio of 1.71 and a debt-to-equity ratio of 0.32.

In other Entellus Medical news, VP Stephen R. Paidosh sold 25,000 shares of the company’s stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $17.54, for a total value of $438,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Timothy B. Petrick sold 2,000 shares of the company’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $18.00, for a total value of $36,000.00. The disclosure for this sale can be found here. Insiders sold a total of 92,150 shares of company stock valued at $1,740,652 over the last quarter. Company insiders own 7.70% of the company’s stock.

Entellus Medical Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Institutional Ownership by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Stock Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related stocks with our FREE daily email newsletter.